J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.